Literature DB >> 19072646

Epigenomics and breast cancer.

Pang-Kuo Lo1, Saraswati Sukumar.   

Abstract

Breast carcinogenesis involves genetic and epigenetic alterations that cause aberrant gene function. Recent progress in the knowledge of epigenomics has had a profound impact on the understanding of mechanisms leading to breast cancer, and consequently the development of new strategies for diagnosis and treatment of breast cancer. Epigenetic regulation has been known to involve three mutually interacting events--DNA methylation, histone modifications and nucleosomal remodeling. These processes modulate chromatin structure to form euchromatin or heterochromatin, and in turn activate or silence gene expression. Alteration in expression of key genes through aberrant epigenetic regulation in breast cells can lead to initiation, promotion and maintenance of carcinogenesis, and is even implicated in the generation of drug resistance. We currently review known roles of the epigenetic machinery in the development and recurrence of breast cancer. Furthermore, we highlight the significance of epigenetic alterations as predictive biomarkers and as new targets of anticancer therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19072646      PMCID: PMC2633440          DOI: 10.2217/14622416.9.12.1879

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  219 in total

1.  Isolation and initial characterization of a novel zinc finger gene, DNMT3L, on 21q22.3, related to the cytosine-5-methyltransferase 3 gene family.

Authors:  U Aapola; K Kawasaki; H S Scott; J Ollila; M Vihinen; M Heino; A Shintani; K Kawasaki; S Minoshima; K Krohn; S E Antonarakis; N Shimizu; J Kudoh; P Peterson
Journal:  Genomics       Date:  2000-05-01       Impact factor: 5.736

2.  Deacetylation of p53 modulates its effect on cell growth and apoptosis.

Authors:  J Luo; F Su; D Chen; A Shiloh; W Gu
Journal:  Nature       Date:  2000-11-16       Impact factor: 49.962

3.  TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers.

Authors:  K E Conway; B B McConnell; C E Bowring; C D Donald; S T Warren; P M Vertino
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

4.  Acetylation of importin-alpha nuclear import factors by CBP/p300.

Authors:  A J Bannister; E A Miska; D Görlich; T Kouzarides
Journal:  Curr Biol       Date:  2000-04-20       Impact factor: 10.834

5.  MethyLight: a high-throughput assay to measure DNA methylation.

Authors:  C A Eads; K D Danenberg; K Kawakami; L B Saltz; C Blake; D Shibata; P V Danenberg; P W Laird
Journal:  Nucleic Acids Res       Date:  2000-04-15       Impact factor: 16.971

6.  Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells.

Authors:  S M Sirchia; A T Ferguson; E Sironi; S Subramanyan; R Orlandi; S Sukumar; N Sacchi
Journal:  Oncogene       Date:  2000-03-16       Impact factor: 9.867

7.  High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer.

Authors:  A T Ferguson; E Evron; C B Umbricht; T K Pandita; T A Chan; H Hermeking; J R Marks; A R Lambers; P A Futreal; M R Stampfer; S Sukumar
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

8.  DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci.

Authors:  M R Rountree; K E Bachman; S B Baylin
Journal:  Nat Genet       Date:  2000-07       Impact factor: 38.330

9.  DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters.

Authors:  K D Robertson; S Ait-Si-Ali; T Yokochi; P A Wade; P L Jones; A P Wolffe
Journal:  Nat Genet       Date:  2000-07       Impact factor: 38.330

10.  Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3.

Authors:  J Li; J Wang; J Wang; Z Nawaz; J M Liu; J Qin; J Wong
Journal:  EMBO J       Date:  2000-08-15       Impact factor: 11.598

View more
  51 in total

1.  Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients.

Authors:  Ayelet Avraham; Ronit Uhlmann; Aino Shperber; Miriam Birnbaum; Judith Sandbank; Avishay Sella; Saraswati Sukumar; Ella Evron
Journal:  Int J Cancer       Date:  2012-04-04       Impact factor: 7.396

Review 2.  The epigenetics of breast cancer.

Authors:  Jovana Jovanovic; Jo Anders Rønneberg; Jörg Tost; Vessela Kristensen
Journal:  Mol Oncol       Date:  2010-04-29       Impact factor: 6.603

3.  Genetic and epigenetic regulation of AHR gene expression in MCF-7 breast cancer cells: role of the proximal promoter GC-rich region.

Authors:  Neal A Englert; Robert J Turesky; Weiguo Han; Erin E Bessette; Simon D Spivack; Michele Caggana; David C Spink; Barbara C Spink
Journal:  Biochem Pharmacol       Date:  2012-06-21       Impact factor: 5.858

4.  Epigenetic modulation of the biophysical properties of drug-resistant cell lipids to restore drug transport and endocytic functions.

Authors:  Sivakumar Vijayaraghavalu; Chiranjeevi Peetla; Shan Lu; Vinod Labhasetwar
Journal:  Mol Pharm       Date:  2012-08-07       Impact factor: 4.939

5.  Breast tumor DNA methylation patterns associated with smoking in the Carolina Breast Cancer Study.

Authors:  Kathleen Conway; Sharon N Edmiston; Eloise Parrish; Christopher Bryant; Chiu-Kit Tse; Theresa Swift-Scanlan; Lauren E McCullough; Pei Fen Kuan
Journal:  Breast Cancer Res Treat       Date:  2017-03-08       Impact factor: 4.872

Review 6.  Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles.

Authors:  Chiranjeevi Peetla; Sivakumar Vijayaraghavalu; Vinod Labhasetwar
Journal:  Adv Drug Deliv Rev       Date:  2013-09-19       Impact factor: 15.470

7.  Mutant p53 binds to estrogen receptor negative promoter via DNMT1 and HDAC1 in MDA-MB-468 breast cancer cells.

Authors:  Rita Arabsolghar; Tayebeh Azimi; Mozhgan Rasti
Journal:  Mol Biol Rep       Date:  2012-12-15       Impact factor: 2.316

8.  High expression of gabarapl1 is associated with a better outcome for patients with lymph node-positive breast cancer.

Authors:  A Berthier; S Seguin; A J Sasco; J Y Bobin; G De Laroche; J Datchary; S Saez; C Rodriguez-Lafrasse; F Tolle; A Fraichard; M Boyer-Guittaut; M Jouvenot; R Delage-Mourroux; F Descotes
Journal:  Br J Cancer       Date:  2010-03-02       Impact factor: 7.640

Review 9.  Targeting epigenetic mechanisms and microRNAs by aspirin and other non steroidal anti-inflammatory agents--implications for cancer treatment and chemoprevention.

Authors:  Eugenia Yiannakopoulou
Journal:  Cell Oncol (Dordr)       Date:  2014-07-05       Impact factor: 6.730

10.  Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.

Authors:  Sivakumar Vijayaraghavalu; Josephine Kamtai Dermawan; Venugopalan Cheriyath; Vinod Labhasetwar
Journal:  Mol Pharm       Date:  2012-12-24       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.